Raymond James Cuts Inozyme Pharma (NASDAQ:INZY) Price Target to $12.00
Inozyme Pharma (NASDAQ:INZY – Free Report) had its price target decreased by Raymond James from $24.00 to $12.00 in a research report report published on Wednesday morning,Benzinga reports. Raymond James currently has an outperform rating on the stock. Several other research analysts have also issued reports on the stock. Wedbush reaffirmed an “outperform” rating and […]
